The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for TNX-102 SL (cyclobenzaprine HCL sublingual tablets) for the management of fibromyalgia.

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) shares are trading lower Tuesday after initially jumping after the company ...

FDA accepts Tonix’s NDA for TNX-102 SL, a non-opioid fibromyalgia treatment. Learn how this potential new drug addresses ...

Tonix Pharmaceuticals (TNXP) announced that the U.S. Food and Drug Administration, FDA, has accepted the filing of its New Drug Application, ...

FDA is expected to assign a Prescription Drug User Fee Act (PDUFA) target action date and announce whether Priority Review ...

Submitted New Drug Application (NDA) to FDA for TNX-102 SL for fibromyalgia based on two statistically significant Phase 3 ...

“This is an exciting time to be joining Tonix as it prepares to receive an FDA decision on its NDA for TNX-102 SL for the management of fibromyalgia,” said Mr. Raudabaugh. “I am ecstatic to work with ...

Tonix Pharma ( (TNXP)) just unveiled an announcement. Tonix Pharmaceuticals is strategically strengthening its leadership team by appointing new executives as it prepares for significant progress ...

Holding announced the expansion of its leadership team to support the launch of TNX-102 SL for the management of ...

Tonix Pharmaceuticals (TNXP ... 102 SL for the management of fibromyalgia submitted to FDA in October 2024; NDA acceptance expected December 2024; Fast Track designation previously granted ...